Want to see IN:MANGALAM full AI Analyst Report?
MANGALAM Stock Chart & Stats
₹30.40
-₹1.02(-0.89%)
At close: 4:00 PM EST
₹30.40
-₹1.02(-0.89%)
Day’s Range― - ―
52-Week Range₹22.70 - ₹85.99
Previous CloseN/A
Volume15.57K
Average Volume (3M)5.11K
Market Cap
₹443.19M
Enterprise Value₹2.05K
Total Cash (Recent Filing)₹7.01M
Total Debt (Recent Filing)₹1.05B
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.05
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.42
Price to Sales (P/S)0.19
P/FCF Ratio-2.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Specialty-Chemicals End MarketsExposure to several downstream industries broadens the potential customer base and reduces reliance on one application. Tartaric acid, tartrates, and other intermediates provide a platform for serving recurring specialty-chemical demand.
Demonstrated Historical ProfitabilityEarlier profitable periods and positive operating cash flow show that the business model can generate earnings and cash under better operating conditions. This provides a foundation for recovery if revenue and margins stabilize.
Positive Equity And Asset BasePositive net worth and a sizable asset base provide an operating foundation and reduce the risk of immediate balance-sheet insolvency. These resources may support production continuity and a recovery plan despite current financial pressure.
Bears Say
Sharp Profitability DeteriorationThe move from modest profitability to deeply negative margins indicates substantial earnings weakness rather than a minor fluctuation. Persistent losses could constrain reinvestment, weaken supplier confidence, and make recovery dependent on improved operating conditions.
Declining And Volatile RevenueA multi-year revenue decline limits operating leverage and makes fixed manufacturing costs harder to absorb. Continued contraction could weaken market position, reduce purchasing efficiency, and prolong pressure on margins across the specialty-chemicals portfolio.
Negative Cash Flow And Higher LeverageNegative operating and free cash flow reduce internal funding capacity while higher leverage raises refinancing and interest-burden risk. Together, they limit flexibility to maintain assets, fund growth, or withstand continued weakness in demand and profitability.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹85.99 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹443.19M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
Mangalam Drugs & Organics Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 84 days.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on Aug 12, 2026. The company reported -₹4.826 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Mangalam Drugs & Organics Ltd. overvalued?
According to Wall Street analysts Mangalam Drugs & Organics Ltd.’s price is currently Overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹4.826 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.333%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mangalam Drugs & Organics Ltd.
Based in Mumbai, India, Mangalam Drugs & Organics Limited, established in 1972, operates as a global pharmaceutical enterprise. The company is engaged in the production and distribution of a diverse range of medications, drugs, and associated pharmaceutical goods, serving both domestic Indian and international markets. Its offerings encompass various active pharmaceutical ingredients (APIs), chemical intermediates, specialized compounds, and impurities, which are crucial for treatments targeting conditions such as malaria, pain and inflammation, high blood pressure, and retroviral infections.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Lasa Supergenerics Ltd.
―
Par Drugs and Chemicals Limited
―
Vaishali Pharma Ltd.
―
Vivimed Labs Limited
―